Rein Therapeutics Inc. RNTX
0.75
0.01
1.35%
as of 25 Sep
- Market cap
- $73.8M
- P/E
- 0.0×
Follow RNTX
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
0.90 | 0.70 | 0.40 | 4.27 |
Net Debt/EBITDA |
0.74 | 0.81 | 0.96 | 7.23 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.64 | 0.10 | 0.59 | 1.36 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.90 | 0.82 | 0.75 | 0.30 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.13) | (0.13) | (0.11) | (0.13) | |
Cash per Share |
0.15 | 0.13 | 0.15 | 0.61 | |
Shareholders Equity per Share |
0.05 | (1.10) | (1.10) | 0.15 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.05 | (1.10) | (1.10) | 0.15 | |
Free Cash Flow |
(3.55) | (3.22) | (3.42) | (8.64) | |
Working Capital |
(0.57) | (1.85) | (8.18) | 31.74 | |
Net Current Asset Value |
(47.35) | (47.92) | (54.25) | (14.32) | |
| Other line items | |||||
Quick Ratio |
0.70 | 0.52 | 0.33 | 4.19 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.13) | (0.13) | (0.11) | (0.13) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
2.60 | 2.44 | 3.71 | 5.25 | |
Average Assets |
78.96 | 43.17 | 41.96 | 61.73 | |
Average Common Equity |
25.71 | (9.35) | (14.27) | 6.60 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates